Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Seattle now holds the second‑highest office vacancy rate in the nation at 26.6%, with some downtown areas soaring past 35% and Pioneer Square reaching 50%. Mayor‑elect Katie Wilson steps into office with bold proposals—including a vacancy tax and office‑to‑housing conversions—amid tech pullbacks, shifting work habits, and investor uncertainty. Despite alarming numbers, signs of resilience remain, offering opportunities for savvy real estate professionals watching this market transform in real time.
Florida lawmakers are once again targeting the fast‑growing litigation‑financing industry with House Bill 1157, a proposal that would restrict how outside investors participate in lawsuits. The bill would limit funder influence, cap their share of settlements, and require new disclosures—especially for foreign‑backed financing. As similar measures emerge nationwide, the outcome could significantly impact professionals across law, insurance, finance, and real estate who depend on predictable risk and regulatory environments.
Starting April 1, Philadelphia homeowners and renters with federal flood insurance will see a 15% reduction in their premiums thanks to the city joining FEMA’s Community Rating System. The discount reflects Philadelphia’s growing investment in flood‑risk mitigation and is expected to save residents and businesses more than $424,000 annually. Beyond easing household expenses, the change also reshapes how real estate and insurance professionals evaluate flood‑zone properties, opening the door to improved affordability and stronger buyer confidence.
Newrez is doubling down on artificial intelligence with a strategic investment in Homevision, an advanced AI underwriting platform designed to automate collateral, income, assets, credit, and full loan decisioning. After seeing Homevision’s MIRA system boost collateral underwriting efficiency, Newrez plans to expand the technology in 2026—signaling a breakthrough year for real-time automated underwriting across the mortgage industry.
A new United Van Lines migration report reveals that Americans are trading big-city ambition for affordability, shorter commutes, and better quality of life—reshaping where and how commercial real estate will grow. Southern and smaller markets continue to attract new residents, but pandemic‑era assumptions of endless demand are fading as rent growth cools and new inventory floods the market. For investors and real estate professionals, the opportunity now lies in affordable housing, modest office parks, value‑focused retail, and support‑industrial spaces like self‑storage.
The 2026 housing market is finally shifting into balance, with economists forecasting rising home sales, improved affordability, and a more diverse buyer pool. Inventory is up, mortgage rates are easing, and demographic changes—from returning first-time buyers to dominant baby boomers—are reshaping demand. New construction is stabilizing, price growth is moderating, and millions of buyers could re-enter the market as rates fall toward 6 percent. For real estate professionals, this rebalanced environment offers fresh opportunities for growth, strategy, and education.
